BR1100358A - Processo para obter preparação purificada de um anticorpo igg preparada usando um sistema de expressão recombinante, preparação purificada em um anticorpo igg, uso da mesma e formulação - Google Patents

Processo para obter preparação purificada de um anticorpo igg preparada usando um sistema de expressão recombinante, preparação purificada em um anticorpo igg, uso da mesma e formulação

Info

Publication number
BR1100358A
BR1100358A BR1100358-8A BR1100358A BR1100358A BR 1100358 A BR1100358 A BR 1100358A BR 1100358 A BR1100358 A BR 1100358A BR 1100358 A BR1100358 A BR 1100358A
Authority
BR
Brazil
Prior art keywords
antibody
purified
column
prepn
igg antibody
Prior art date
Application number
BR1100358-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Ian Nicholas Ramage
Geoffrey Allen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR1100358(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Priority to BR1100358-8A priority Critical patent/BR1100358A/pt
Publication of BR1100358A publication Critical patent/BR1100358A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR1100358-8A 1990-10-17 1997-04-28 Processo para obter preparação purificada de um anticorpo igg preparada usando um sistema de expressão recombinante, preparação purificada em um anticorpo igg, uso da mesma e formulação BR1100358A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR1100358-8A BR1100358A (pt) 1990-10-17 1997-04-28 Processo para obter preparação purificada de um anticorpo igg preparada usando um sistema de expressão recombinante, preparação purificada em um anticorpo igg, uso da mesma e formulação

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin
BR1100358-8A BR1100358A (pt) 1990-10-17 1997-04-28 Processo para obter preparação purificada de um anticorpo igg preparada usando um sistema de expressão recombinante, preparação purificada em um anticorpo igg, uso da mesma e formulação

Publications (1)

Publication Number Publication Date
BR1100358A true BR1100358A (pt) 2000-03-28

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
BR1100358-8A BR1100358A (pt) 1990-10-17 1997-04-28 Processo para obter preparação purificada de um anticorpo igg preparada usando um sistema de expressão recombinante, preparação purificada em um anticorpo igg, uso da mesma e formulação

Country Status (29)

Country Link
US (1) US5644036A (enExample)
EP (1) EP0504363B2 (enExample)
JP (1) JP2638680B2 (enExample)
KR (2) KR960015399B1 (enExample)
AT (2) ATA900791A (enExample)
AU (3) AU658926B2 (enExample)
BE (1) BE1004226A5 (enExample)
BR (1) BR1100358A (enExample)
CA (1) CA2069481C (enExample)
CH (2) CH681455A5 (enExample)
DE (1) DE69128774T3 (enExample)
DK (1) DK0504363T4 (enExample)
ES (2) ES2112865T5 (enExample)
FI (2) FI110003B (enExample)
FR (2) FR2668164A1 (enExample)
GB (2) GB9022547D0 (enExample)
GR (3) GR910100425A (enExample)
HU (1) HUT64601A (enExample)
IE (1) IE913560A1 (enExample)
IL (3) IL99761A0 (enExample)
IT (1) IT1250064B (enExample)
LU (1) LU88122A1 (enExample)
MX (1) MX9203794A (enExample)
MY (2) MY136210A (enExample)
NZ (2) NZ240247A (enExample)
PT (2) PT99248B (enExample)
TW (1) TW283710B (enExample)
WO (1) WO1992007084A1 (enExample)
ZA (2) ZA926191B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
MY115415A (en) * 1991-10-15 2003-06-30 Wellcome Found Medicaments.
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
EP0841942B2 (fr) † 1995-08-01 2007-12-12 Sanofi Pasteur Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP1380589A4 (en) 2001-03-09 2004-09-01 Chugai Pharmaceutical Co Ltd PROTEIN CLEANING METHOD
DE60213248T2 (de) * 2001-06-05 2006-11-30 Genetics Institute, LLC, Cambridge Verfahren zur reinigung hochanionischer proteine
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
US8420789B2 (en) 2002-09-11 2013-04-16 Chugai Seiyaku Kabushiki Kaisha Method for removing DNA contaminants from a protein-containing sample
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗ｃｄ５２抗体治療法
CN104610422A (zh) * 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
KR101537840B1 (ko) 2009-05-13 2015-07-22 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
EP3345620B1 (en) 2009-05-13 2024-08-28 Genzyme Corporation Methods and compositions for treating lupus
US20130178608A1 (en) * 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
US20130096284A1 (en) 2010-06-21 2013-04-18 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
RU2714967C2 (ru) 2013-12-27 2020-02-21 Чугаи Сейяку Кабусики Кайся Способ очистки антител с низкой изоэлектрической точкой
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
WO2017022651A1 (ja) 2015-07-31 2017-02-09 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
ES2994244T3 (en) 2016-07-25 2025-01-21 Cephalon Llc Affinity chromatography wash buffer
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
WO2020203718A1 (ja) 2019-03-29 2020-10-08 旭化成メディカル株式会社 タンパク質の精製方法
US12383884B2 (en) 2019-04-08 2025-08-12 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
TW202104244A (zh) 2019-04-10 2021-02-01 日商中外製藥股份有限公司 Fc區域改變抗體的純化方法
CN117241881A (zh) 2021-06-10 2023-12-15 三菱化学株式会社 合成吸附剂、抗体的纯化方法和抗体的制造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
DE10199051I2 (de) * 1988-02-12 2005-05-04 Btg Int Ltd Modifizierte Antik¦rper.

Also Published As

Publication number Publication date
CH681305A5 (enExample) 1993-02-26
DK0504363T3 (da) 1998-09-21
FI922824L (fi) 1992-06-17
PT99248B (pt) 1999-04-30
AU4521897A (en) 1998-02-12
GR910100425A (el) 1992-09-25
IL102726A (en) 2002-08-14
ZA926191B (en) 1993-04-16
AU658926B2 (en) 1995-05-04
FI110002B (fi) 2002-11-15
IT1250064B (it) 1995-03-30
JP2638680B2 (ja) 1997-08-06
DE69128774T2 (de) 1998-06-04
KR920703108A (ko) 1992-12-17
US5644036A (en) 1997-07-01
IE913560A1 (en) 1992-04-22
FI922380L (fi) 1992-05-25
CA2069481C (en) 2003-07-29
EP0504363A1 (en) 1992-09-23
IL102726A0 (en) 1993-01-31
IL99761A0 (en) 1992-08-18
DE69128774D1 (de) 1998-02-26
HU9202000D0 (en) 1992-10-28
GB2253397A (en) 1992-09-09
GR920100471A (el) 1994-06-30
BE1004226A5 (fr) 1992-10-13
AU7024294A (en) 1995-01-05
TW283710B (enExample) 1996-08-21
WO1992007084A1 (en) 1992-04-30
FI922824A0 (fi) 1992-06-17
ITRM910788A0 (it) 1991-10-16
DK0504363T4 (da) 2007-05-29
AU716402B2 (en) 2000-02-24
ES2081742A1 (es) 1996-03-01
HUT64601A (en) 1994-01-28
FR2668164A1 (fr) 1992-04-24
FI110003B (fi) 2002-11-15
NZ244114A (en) 1995-06-27
GB9209529D0 (en) 1992-07-01
FR2677997A1 (fr) 1992-12-24
MY119030A (en) 2005-03-31
FI922380A0 (fi) 1992-05-25
ES2112865T5 (es) 2007-09-16
KR100193314B1 (ko) 1999-06-15
ITRM910788A1 (it) 1993-04-16
ES2081742B1 (es) 1996-10-01
FR2668164B1 (enExample) 1995-04-14
KR960015399B1 (ko) 1996-11-13
CA2069481A1 (en) 1992-04-18
PT99248A (pt) 1993-06-30
ATE162552T1 (de) 1998-02-15
NZ240247A (en) 1994-03-25
ES2112865T3 (es) 1998-04-16
DE69128774T3 (de) 2007-08-16
GR3026588T3 (en) 1998-07-31
GB9022547D0 (en) 1990-11-28
PT100988A (pt) 1994-02-28
JPH05504579A (ja) 1993-07-15
PT100988B (pt) 1999-08-31
EP0504363B2 (en) 2007-02-07
LU88122A1 (fr) 1993-03-15
AU8729491A (en) 1992-05-20
ZA918259B (en) 1993-04-16
CH681455A5 (enExample) 1993-03-31
MX9203794A (es) 1992-07-01
ATA900791A (de) 1996-06-15
MY136210A (en) 2008-08-29
AU2532192A (en) 1993-02-11
AU649078B2 (en) 1994-05-12
EP0504363B1 (en) 1998-01-21

Similar Documents

Publication Publication Date Title
BR1100358A (pt) Processo para obter preparação purificada de um anticorpo igg preparada usando um sistema de expressão recombinante, preparação purificada em um anticorpo igg, uso da mesma e formulação
Grandics et al. Phosphorylation invivo of rat hepatic glucocorticoid receptor
EP0185034A4 (enExample)
EP0239565A3 (en) Method of and apparatus for separating proteins
EP0087686A3 (en) Homogeneous human immune interferon and process therefor
US5338834A (en) Ultrapure human interleukin-6
RU95112503A (ru) Способ выделения предварительно отобранного гемоглобина и очищенный препарат гемоглобина
Dimitrijevic et al. Purification and characterization of an estrogen-binding peroxidase from human fetuses
Van Kamp et al. One-step preparation of the polypeptide chains of α-crystallin
DENG PURIFICATION OF HUMAN INTERFERON-? BY ANTIBODY AFFINITY CHROMATOGRAPY
Kurochkina et al. Isolation of modified histone H3 from ultraviolet-irradiated deoxyribonucleoprotein by reversed-phase high-performance liquid chromatography
DE69116582D1 (de) Verfahren zur Herstellung von rekombinantem Humaninterferon-beta in reiner Form
Friedlander et al. A modified procedure for isolation of chick intestinal calciumbinding protein
ES2068392T3 (es) Procedimiento de purificacion de interferon.
LUSTENBERGER et al. Purification of Glucocorticoid Receptor from Rabbit Liver by Steroid Affinity Chromatography
DK318086A (da) Praeparat til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadant praeparat

Legal Events

Date Code Title Description
AN Processing applications according to articles 230 and 231 of law 9279/96: notification of filing an application
FGAN Processing applications according to articles 230 and 231 of law 9.279/96: granting
NB Patent issued - articles 230 and 231 of law 9279/96